...
首页> 外文期刊>Thorax: The Journal of the British Thoracic Society >Can mandibular advancement devices be a satisfactory substitute for short term use in patients on nasal continuous positive airway pressure?
【24h】

Can mandibular advancement devices be a satisfactory substitute for short term use in patients on nasal continuous positive airway pressure?

机译:下颌前移装置是否可以令人满意地替代鼻腔持续气道正压通气的患者?

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Mandibular advancement devices (MADs) can successfully control both snoring and obstructive sleep apnoea (OSA). Many patients on nasal continuous positive airway pressure (NCPAP) for OSA would like a more portable alternative, even if only temporarily. This study assesses what proportion of patients with OSA already on NCPAP can successfully use a MAD for short periods (up to 1 month) as a temporary alternative to NCPAP. METHODS: Fifty patients with OSA, already on NCPAP for at least 3 months, were recruited by invitation. They were provided with a simple fixed MAD estimated to provide 75% of maximum mandibular protrusion. Sleep studies using a portable home recorder were performed on and after three nights without NCPAP to provide control data. Following acclimatisation to the MAD, sleep studies were also planned after 3, 7, and 28 days while using the MAD. If their overnight >4% SaO(2) dips per hour deteriorated to >20 or the Epworth sleepiness score (ESS) rose to >9 (or increased by >4 over baseline) on nights 3 or 7, they were then deemed to have failed the trial and were withdrawn. RESULTS: Of the 50 patients entered, one had inadequate teeth for a MAD and 31 gave up trying to use the device during the acclimatisation period because of side effects. Of the 18 prepared to use the device, two patients failed at night 3, five at night 7, and two at night 28. Thus, nine patients remained controlled by our criteria at night 28. On average, sleep study indices while using the MAD were poor compared with the night on NCPAP. CONCLUSIONS: Simple MADs are poorly tolerated by patients with OSA already on NCPAP. OSA was adequately controlled by our criteria in 32% of those recruited for the equivalent of a weekend, in 22% for 1 week, and in 18% for up to 1 month. Better tolerated devices would be likely to improve on these figures.
机译:背景:下颌前移装置(MAD)可以成功控制打和阻塞性睡眠呼吸暂停(OSA)。鼻腔持续气道正压通气(NCPAP)治疗OSA的许多患者,即使只是暂时性的,也希望有一种更便携的替代方法。这项研究评估了已经使用NCPAP的OSA患者中有多少比例可以在短时间内(长达1个月)成功使用MAD替代NCPAP。方法:通过邀请招募了50名已经接受NCPAP治疗至少3个月的OSA患者。他们被提供了一个简单的固定MAD,估计可以提供最大下颌突突的75%。在没有NCPAP提供控制数据的情况下,在三晚及之后使用便携式家用记录仪进行睡眠研究。在适应MAD之后,还计划在3、7和28天后使用MAD进行睡眠研究。如果他们的过夜> 4%SaO(2)每小时浸水恶化至> 20,或在3或7晚的爱泼思嗜睡分数(ESS)上升至> 9(或比基线增加> 4),则认为他们患有审判失败并被撤回。结果:在进入的50例患者中,有1例患MAD的牙齿不足,有31例由于副作用而放弃尝试在适应期使用该设备。在准备使用该设备的18位患者中,有2位患者在第3夜失败,有5位在第7夜失败,有2位在第28夜失败。因此,在第28晚上,有9位患者仍受我们的标准控制。平均而言,使用MAD时的睡眠研究指标与NCPAP的夜晚相比,这里的人很差。结论:已经接受NCPAP治疗的OSA患者对简单MAD的耐受性较差。我们的标准对OSA进行了充分控制,其中32%的受聘者相当于一个周末,22%的受雇者为1周,18%的受雇者为1个月。容忍度更高的设备可能会在这些数字上有所改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号